Login to Your Account

Icagen Falls 73 Percent After DMC Analysis Of ICA-17043

By Karen Pihl-Carey

Monday, August 7, 2006
Shares of Icagen Inc. plunged 73.6 percent Friday following news that an independent Data Monitoring Committee recommended the company stop treating half the patients in a Phase III trial of ICA-17043 for sickle cell disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription